Literature DB >> 8613256

Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator.

A R Brasier1, J Li, K A Wimbish.   

Abstract

Angiotensinogen encodes the only known precursor of angiotensin II, a critical regulator of the cardiovascular system. Transcriptional control of angiotensinogen in hepatocytes is an important regulator of circulating angiotensinogen concentrations. Angiotensinogen transcription is increased by the inflammatory cytokine tumor necrosis factor (TNF)-alpha by a nuclear factor-kappaB-like protein binding to an inducible enhancer called the acute-phase response element. By gel mobility shift assays, we observe two specific acute-phase response element-binding complexes, C1 and C2. The abundance of C2 is not changed by TNF treatment. In contrast, C1 is faintly detected in untreated cells, and its abundance increases by fivefold after stimulation. We identify the nuclear factor-kappaB subunits in these complexes using subunit-specific antibodies in the gel mobility "supershift" assay. The transcriptionally inert nuclear factor-kappaB DNA-binding subunit NF-kappaB1 is present in both control and stimulated hepatocyte nuclei. Its abundance changes weakly upon TNF stimulation. In contrast, the potent transactivating protein Rel A is not found in unstimulated hepatocyte nuclei and is recruited by TNF-alpha into the C1 DNA-binding complex. Overexpression of Rel A results in acute-phase response element transcription. Cotransfection of a chimeric GAL4-Rel A protein with GAL4 DNA-binding sites is a strategy that allows for selective study of Rel A. The GAL4:Rel A chimera is a TNF-alpha-inducible transactivator. Deletion of the amino-terminal 254 amino acids of Rel A produces a constitutive activator (that is no longer TNF-alpha inducible). The cytokine induction of Rel A, then, is mediated through its amino-terminal 254 amino acids. We conclude that Rel A:NF-kappaB1 is a crucial cytokine-inducible transcription factor complex regulating angiotensinogen gene synthesis in hepatocytes and may be involved in controlling the activity of the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613256     DOI: 10.1161/01.hyp.27.4.1009

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.

Authors:  Jeffrey P Cardinale; Srinivas Sriramula; Romain Pariaut; Anuradha Guggilam; Nithya Mariappan; Carrie M Elks; Joseph Francis
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

2.  Immunosuppressive treatment protects against angiotensin II-induced renal damage.

Authors:  Dominik N Muller; Erdenechimeg Shagdarsuren; Joon-Keun Park; Ralf Dechend; Eero Mervaala; Franziska Hampich; Anette Fiebeler; Xinsheng Ju; Piet Finckenberg; Jürgen Theuer; Christiane Viedt; Joerg Kreuzer; Harald Heidecke; Hermann Haller; Martin Zenke; Friedrich C Luft
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions.

Authors:  Yuri Ozawa; Hiroyuki Kobori; Yuki Suzaki; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2006-06-27

Review 4.  Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor.

Authors:  A R Brasier; M Jamaluddin; Y Han; C Patterson; M S Runge
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

5.  TNFR1-deficient mice display altered blood pressure and renal responses to ANG II infusion.

Authors:  Chun Cheng Andy Chen; Paulina L Pedraza; Shoujin Hao; Charles T Stier; Nicholas R Ferreri
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-25

6.  Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.

Authors:  Yang Yu; Zhi-Hua Zhang; Shun-Guang Wei; Robert M Weiss; Robert B Felder
Journal:  Hypertension       Date:  2011-11-14       Impact factor: 10.190

7.  Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats.

Authors:  Linda T Tran; Kathleen M MacLeod; John H McNeill
Journal:  Mol Cell Biochem       Date:  2009-05-07       Impact factor: 3.396

8.  TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis.

Authors:  Clemens Duerrschmid; Jeffrey R Crawford; Erin Reineke; George E Taffet; Joann Trial; Mark L Entman; Sandra B Haudek
Journal:  J Mol Cell Cardiol       Date:  2013-01-18       Impact factor: 5.000

9.  Role of the immune system in hypertension: modulation by dietary antioxidants.

Authors:  Sudesh Vasdev; Jennifer Stuckless; Vernon Richardson
Journal:  Int J Angiol       Date:  2011-12

Review 10.  The pediatric nephrotic syndrome spectrum: clinical homogeneity and molecular heterogeneity.

Authors:  Asher D Schachter
Journal:  Pediatr Transplant       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.